Tiziana life sciences announces presentations on intranasal foralumab at the “preserving the brain” scientific conference and exhibit at the fondazione prada in milan

New york, sept. 28, 2022 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that poster presentations on intranasal foralumab were presented at the “preserving the brain” scientific conference and exhibit held at the fondazione prada in milan, italy. in addition, the first secondary progressive multiple sclerosis (spms) patient receiving intranasal foralumab was interviewed by dr. howard l. weiner of brigham and women's hospital, who is also the chairman of tiziana's scientific advisory board.
TLSA Ratings Summary
TLSA Quant Ranking